Table 7.

Cases with HBV reactivation-related hepatic failure among co-infected patients treated by DAAs

#	Age (years)/gender	Treatment for HCV (GT)	Severity, ALT levels	Treatment for HBV (GT/HBeAg)/outcome	Authors (year) [references]
HBsAg-positive patients treated by DAAs
1	57/Female	Daclatasvir/Asunaprevir (unknown)	Hepatic failure, ALT 2114 IU/L	Entecavir (unknown/unknown)/death	Holmes et al. (2017) [88]
2	73/Female	Daclatasvir/Asunaprevir (unknown)	Hepatic failure, ALT 462 IU/L	Entecavir (unknown/unknown)/death	Holmes et al. (2017) [88]
3	53/Female	Sofosbuvir/Ribavirin (GT1)	ALT 1417 IU/L	No description (unknown/HBeAg-)/no description	Holmes et al. (2017) [88]
4	53/Male	Ledipasvir/Sofosbuvir (GT1) [co-infection with HIV]	ALT 1026 IU/L	Tenofovir (GTD/HBeAg-)/alive	De Monte et al. (2016) [89]
HBsAg-negative patients treated by DAAs
5	59/Female	Sofosbuvir/Simeprevir (GT1b)	Hepatic failure, ALT 2263 IU/L	Tenofovir (unknown/unknown)/liver transplantation	Ende et al. (2015) [103]
6	83/Female	Daclatasvir/Asunaprevir (GT1b)	Hepatic failure, ALT 1066 IU/L	Entecavir (GTB1/unknown)/death	Hayashi et al. (2016) [104]

GT genotype, ALT alanine aminotransferase, HBeAg hepatitis B e antigen